| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YMGME.2015.11.001 |
| P698 | PubMed publication ID | 26597321 |
| P50 | author | Zoheb Kazi | Q57558851 |
| Jeffrey A Bluestone | Q87186905 | ||
| P2093 | author name string | Laurence A Turka | |
| Pranoot Tanpaiboon | |||
| Stephen Holland | |||
| Priya S Kishnani | |||
| Chester B Whitley | |||
| Barbara K Burton | |||
| Patricia I Dickson | |||
| Jessica J Lee | |||
| Anne R Pariser | |||
| Yow-Ming Wang | |||
| Donna Griebel | |||
| Rekha Abichandani | |||
| Amy Rosenberg | |||
| Melissa Hogan | |||
| Alexandra Freitas | |||
| Derek Gavin | |||
| Jeanine J Utz | |||
| Laurie Muldowney | |||
| Maureen Dewey | |||
| P2860 | cites work | Clarifying lysosomal storage diseases | Q24620532 |
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]) | Q28267383 | ||
| Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease | Q30489156 | ||
| The emerging phenotype of long-term survivors with infantile Pompe disease. | Q30573752 | ||
| Intravenous immunoglobulin therapy: how does IgG modulate the immune system? | Q33405903 | ||
| Enzyme replacement therapy in Fabry disease: a randomized controlled trial | Q33949356 | ||
| Common and uncommon pathogenic cascades in lysosomal storage diseases | Q33966917 | ||
| Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome | Q34456578 | ||
| Prevalence of lysosomal storage disorders | Q34489300 | ||
| The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease | Q34629805 | ||
| Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. | Q34794660 | ||
| Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease | Q35087282 | ||
| Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. | Q35558692 | ||
| Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience | Q35752654 | ||
| Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers | Q35836295 | ||
| CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy | Q36030998 | ||
| Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment | Q36338254 | ||
| Genetic risk factors for inhibitors to factors VIII and IX. | Q36661811 | ||
| Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy | Q36953239 | ||
| Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. | Q37012107 | ||
| Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants | Q37040458 | ||
| Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease | Q37097386 | ||
| Lysosomal disorders: from storage to cellular damage | Q37359176 | ||
| Newborn screening for lysosomal storage disorders and other neuronopathic conditions | Q37518525 | ||
| Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. | Q37977140 | ||
| The impact of antibodies in late-onset Pompe disease: a case series and literature review | Q38011881 | ||
| Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options | Q38206175 | ||
| Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process | Q42033075 | ||
| A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease | Q42603793 | ||
| Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. | Q43180517 | ||
| IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome | Q43530570 | ||
| Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta | Q45085878 | ||
| Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease | Q45877276 | ||
| Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease | Q46687028 | ||
| Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting | Q46735411 | ||
| The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. | Q47674845 | ||
| Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. | Q48413831 | ||
| Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). | Q48463259 | ||
| Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. | Q52007706 | ||
| Elimination of antibodies to recombinant enzyme in Pompe's disease. | Q55051298 | ||
| Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS) | Q57785496 | ||
| Measuring relative lysosomal volume for monitoring lysosomal storage diseases | Q62401728 | ||
| Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats | Q77920297 | ||
| A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I | Q82749809 | ||
| Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? | Q82865841 | ||
| Newborn screening for lysosomal storage disorders | Q83116248 | ||
| Immune modulation in Pompe disease treated with enzyme replacement therapy | Q84997571 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 66-83 | |
| P577 | publication date | 2015-11-10 | |
| P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
| P1476 | title | Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction | |
| P478 | volume | 117 |
| Q91826241 | A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I |
| Q47131823 | A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I. |
| Q91437144 | An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease |
| Q98735560 | Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort |
| Q41620233 | Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta |
| Q64058417 | Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy |
| Q40173979 | Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report. |
| Q59055925 | Cryo-EM structure of a fungal mitochondrial calcium uniporter |
| Q57174028 | Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY |
| Q41009140 | Delayed Infusion Reactions to Enzyme Replacement Therapies |
| Q37619231 | Disease models for the development of therapies for lysosomal storage diseases |
| Q64932153 | Enzyme replacement therapies: what is the best option? |
| Q90094501 | Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America |
| Q45437801 | Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story. |
| Q37394520 | Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients |
| Q38684097 | Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives |
| Q48630939 | Modulating the immune system through nanotechnology. |
| Q89863646 | Persistent dyslipidemia in treatment of lysosomal acid lipase deficiency |
| Q38760096 | Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems |
| Q45324511 | Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in children affected by Pompe Disease |
| Q64072336 | Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I |
| Q38621461 | Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease |
| Q64039369 | Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease |
| Q49209110 | Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease |
| Q87305419 | The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders |
| Q57192798 | Validation of an Immunoassay for Anti-thymidine Phosphorylase Antibodies in Patients with MNGIE Treated with Enzyme Replacement Therapy |
Search more.